Characteristics | All (n = 338, %) |
---|---|
At the time of diagnosis | |
FIGO stage | |
IC | 19 (5.6) |
II | 29 (8.6) |
III | 169 (50.0) |
IV | 121 (35.8) |
Initial serum CA-125 a, IU/ml | |
Median (IQR) | 878.0 (289.0–2433.0) |
Primary treatment strategy | |
Primary debulking surgery | 225 (66.6) |
Neoadjuvant chemotherapy | 113 (33.4) |
At the time of surgery | |
Age, years | |
Mean ± SD | 57.8 ± 11.2 |
BMI, kg/m2 | |
Median (IQR) | 23.2 (20.9–25.4) |
Underweight (<18.5) | 24 (7.1) |
Normal (18.5–22.9) | 134 (39.6) |
Overweight (23.0–24.9) | 81 (24.0) |
Obesity (≥25.0) | 99 (29.3) |
Comorbidities | |
Hypertension | 58 (17.2) |
Diabetes | 19 (5.6) |
Liver disease | 7 (2.1) |
Heart disease | 9 (2.7) |
Renal disease | 2 (0.6) |
Vascular disease | 2 (0.6) |
Neurologic disease | 5 (1.5) |
Asthma | 2 (0.6) |
ASA classification | |
1 | 65 (19.2) |
2 | 220 (65.1) |
3 | 52 (15.4) |
4 | 1 (0.3) |
Surgical complexity score | |
Median (IQR) | 6 (4–9) |
Low (≤3) | 33 (9.8) |
Intermediate (4–7) | 175 (51.8) |
High (≥8) | 130 (38.5) |
Residual tumor after PDS/IDS | |
Complete cytoreduction (R0) | 253 (74.9) |
< 1 cm | 48 (14.2) |
1–2 cm | 22 (6.5) |
≥ 2 cm | 15 (4.4) |